An analysis of the possible protective effect of antipsychotics for SARS-CoV-2 in patients under treatment for severe mental illnesses.
作者信息
Prokopez Cintia R, Vallejos Miguel, Lopredo Lorena S, Sfriso Luciano E, Chiapella Luciana C, Arce Claudio, Corral Ricardo M, Cuesta Manuel J, Farinola Romina, Alomo Martín
机构信息
Braulio Aurelio Moyano Neuropsychiatric Hospital, Buenos Aires, Argentina; Institute of Pharmacology, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
José Tiburcio Borda Hospital, Buenos Aires, Argentina.
出版信息
Schizophr Res. 2021 Jul;233:99-100. doi: 10.1016/j.schres.2021.06.019. Epub 2021 Jun 23.
Abstract
摘要
相似文献
1
An analysis of the possible protective effect of antipsychotics for SARS-CoV-2 in patients under treatment for severe mental illnesses.对正在接受严重精神疾病治疗的患者使用抗精神病药物对SARS-CoV-2可能产生的保护作用的分析。
Schizophr Res. 2021 Jul;233:99-100. doi: 10.1016/j.schres.2021.06.019. Epub 2021 Jun 23.
2
Decline In New Starts Of Psychotropic Medications During The COVID-19 Pandemic.精神类药物在 COVID-19 大流行期间新处方数量下降。
Health Aff (Millwood). 2021 Jun;40(6):904-909. doi: 10.1377/hlthaff.2021.00028.
3
Antipsychotics modified COVID-19 prevalence in hospitalized patients diagnosed with mental illnesses.抗精神病药物改变了被诊断患有精神疾病的住院患者中新冠病毒病的患病率。
Gen Hosp Psychiatry. 2023 Sep-Oct;84:250-252. doi: 10.1016/j.genhosppsych.2023.04.009. Epub 2023 Apr 20.
4
Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospective epidemiological study in a representative Spanish population.接受抗精神病药物治疗的严重精神障碍患者感染SARS-CoV2的风险较低：一项针对西班牙代表性人群的回顾性流行病学研究。
Schizophr Res. 2021 Mar;229:53-54. doi: 10.1016/j.schres.2021.02.002. Epub 2021 Feb 19.
5
Letter on: "Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospective epidemiological study in a representative Spanish population".关于“接受抗精神病药物治疗的严重精神障碍患者感染 SARS-CoV-2 的风险较低：一项针对西班牙代表性人群的回顾性流行病学研究”的信函
Schizophr Res. 2021 Jul;233:97-98. doi: 10.1016/j.schres.2021.06.036. Epub 2021 Jun 26.
6
Olanzapine, risperidone and quetiapine: Do these atypical antipsychotics have a protective effect for SARS-CoV-2?奥氮平、利培酮和喹硫平：这些非典型抗精神病药物对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）有保护作用吗？
Schizophr Res. 2022 Mar;241:140-141. doi: 10.1016/j.schres.2022.01.035. Epub 2022 Jan 24.
7
Can antipsychotic use protect from COVID-19?使用抗精神病药物能预防新型冠状病毒肺炎吗？
Schizophr Res. 2021 Oct;236:1-2. doi: 10.1016/j.schres.2021.07.035. Epub 2021 Jul 30.
8
An overall protective effect of antipsychotic drugs against COVID-19 seems implausible.抗精神病药物对新冠病毒疾病具有全面保护作用，这似乎不太可信。
Schizophr Res. 2022 May;243:486-488. doi: 10.1016/j.schres.2021.12.020. Epub 2021 Dec 22.
9
10
Antipsychotics, COVID-19, and Secondary Healthcare Databases: Revisiting the Pandemic.抗精神病药物、新冠疫情与二级医疗保健数据库：重访大流行
Int J Neuropsychopharmacol. 2024 Jul 1;27(7). doi: 10.1093/ijnp/pyae026.
引用本文的文献
1
Adherence to Antipsychotics, COVID-19 and Stigma: A Rainbow After the Storm?抗精神病药物的依从性、COVID-19与污名化：暴风雨后的彩虹？
Actas Esp Psiquiatr. 2025 May;53(3):616-620. doi: 10.62641/aep.v53i3.1813.
2
Antipsychotics, COVID-19, and Secondary Healthcare Databases: Revisiting the Pandemic.抗精神病药物、新冠疫情与二级医疗保健数据库：重访大流行
Int J Neuropsychopharmacol. 2024 Jul 1;27(7). doi: 10.1093/ijnp/pyae026.
3
Outpatient Antipsychotic Use and Severe COVID-19: Avoiding the Impact of Age in a Real-World Data Study.门诊抗精神病药使用与严重 COVID-19：在真实世界数据研究中避免年龄的影响。
Int J Neuropsychopharmacol. 2024 Apr 1;27(4). doi: 10.1093/ijnp/pyae020.
4
Exploring the Impact of COVID-19 Vaccination on Patients Taking Clozapine.探索新冠疫苗接种对服用氯氮平患者的影响。
Innov Clin Neurosci. 2023 Jan-Mar;20(1-3):32-38.
5
Epidemiology of infection, transmission and COVID-19 outcomes among mental health users and workers in a comprehensive network of long-term mental health facilities: Retrospective observational population-base study.长期精神卫生设施综合网络中精神卫生使用者和工作人员的感染、传播及 COVID-19 结局的流行病学：回顾性观察性基于人群的研究。
Schizophr Res. 2023 Apr;254:1-7. doi: 10.1016/j.schres.2023.01.020. Epub 2023 Jan 20.
6
Clozapine Therapy and COVID-19: A Systematic Review of the Prevalence Rates, Health Outcomes, Hematological Markers, and Patient Perspectives.氯氮平治疗与 COVID-19：患病率、健康结局、血液学标志物及患者观点的系统评价。
Schizophr Bull. 2023 Jan 3;49(1):53-67. doi: 10.1093/schbul/sbac148.
7
Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State-wide Psychiatric Hospital System.在纽约州一家精神科医院系统中，长期住院的严重精神疾病患者使用精神药物与 COVID-19 感染风险之间的关联。
JAMA Netw Open. 2022 May 2;5(5):e2210743. doi: 10.1001/jamanetworkopen.2022.10743.
8
Clozapine and COVID-19 Vaccination: Effects on blood levels and leukocytes. An observational cohort study.氯氮平和 COVID-19 疫苗接种：对血液水平和白细胞的影响。一项观察性队列研究。
Acta Psychiatr Scand. 2022 Aug;146(2):168-178. doi: 10.1111/acps.13428. Epub 2022 Apr 1.
9
Olanzapine, risperidone and quetiapine: Do these atypical antipsychotics have a protective effect for SARS-CoV-2?奥氮平、利培酮和喹硫平：这些非典型抗精神病药物对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）有保护作用吗？
Schizophr Res. 2022 Mar;241:140-141. doi: 10.1016/j.schres.2022.01.035. Epub 2022 Jan 24.
10
COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review.严重精神疾病患者中与COVID-19相关的死亡风险：一项系统的批判性综述。
Front Psychiatry. 2022 Jan 13;12:798554. doi: 10.3389/fpsyt.2021.798554. eCollection 2021.
本文引用的文献
1
Towards a pharmacochemical hypothesis of the prophylaxis of SARS-CoV-2 by psychoactive substances.从精神活性物质预防 SARS-CoV-2 的药理学假说角度探讨。
Med Hypotheses. 2020 Nov;144:110025. doi: 10.1016/j.mehy.2020.110025. Epub 2020 Jun 23.
2
Psychosis Treatment During COVID-19 Pandemic and the Potential Role of Phenothiazines: A Call for Research Studies.新冠疫情期间的精神病治疗及吩噻嗪类药物的潜在作用：呼吁开展研究
J Clin Psychopharmacol. 2020 Nov/Dec;40(6):641-642. doi: 10.1097/JCP.0000000000001310.
3
Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.意大利伦巴第地区重症监护病房中 COVID-19 患者死亡的相关危险因素。
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355. doi: 10.1001/jamainternmed.2020.3539.
4
Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders.通过药物再利用预防新冠病毒：来自用于精神障碍的处方药的理论依据。
Drug Discov Today. 2020 Aug;25(8):1287-1290. doi: 10.1016/j.drudis.2020.06.022. Epub 2020 Jun 25.
5
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.一种 SARS-CoV-2 蛋白相互作用图谱揭示了药物再利用的靶标。
Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9. Epub 2020 Apr 30.
6
Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.危重症和死亡 COVID-19 病例的风险因素：系统文献回顾和荟萃分析。
J Infect. 2020 Aug;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021. Epub 2020 Apr 23.
7
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.113 例新冠肺炎死亡患者的临床特征：回顾性研究。
BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091.
8
Size of burden of schizophrenia and psychotic disorders.精神分裂症和精神障碍的负担规模。
Eur Neuropsychopharmacol. 2005 Aug;15(4):399-409. doi: 10.1016/j.euroneuro.2005.04.009.
Zotero 插件